Next Broadcast:

TPP and Pharma
A big sticking point in the negotiations over the Trans-Pacific Partnership involved biologics medicines and vaccines created from living organisms. The dispute centered on patent protection: how many years drug companies should have before facing competition from generics. The negotiators ended up with a complicated compromise that gives drug makers five to eight years of protection. But nobody is really happy with the outcome.

Thu, Oct 8, 2015 -- 11:00pm

Recently on All Things Considered:

Become a KQED sponsor